Template:Monoclonals for immune system: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
en>Jonesey95 m Fix Linter errors related to text color in dark mode; this generally works but may cause problems, in which case revert or try specifying a different CSS value. |
||
| Line 12: | Line 12: | ||
| list1 = | | list1 = | ||
* ''[[Immunosuppression]]'': [[Abrilumab]] | * ''[[Immunosuppression]]'': [[Abrilumab]] | ||
* [[Adalimumab]] | * [[Adalimumab]]<sup>#</sup> | ||
* [[Anifrolumab]] | * [[Anifrolumab]] | ||
* [[Atorolimumab]] | * [[Atorolimumab]] | ||
* [[Avelumab]] | * [[Avelumab]] | ||
* [[Avdoralimab]] | |||
* [[Belimumab]] | * [[Belimumab]] | ||
* [[Bleselumab]] | * [[Bleselumab]] | ||
| Line 31: | Line 32: | ||
* [[Lenzilumab]] | * [[Lenzilumab]] | ||
* [[Lerdelimumab]] | * [[Lerdelimumab]] | ||
* [[Lirentelimab]] | |||
* [[Lirilumab]] | * [[Lirilumab]] | ||
* [[Mavrilimumab]] | * [[Mavrilimumab]] | ||
| Line 44: | Line 46: | ||
* [[Sifalimumab]] | * [[Sifalimumab]] | ||
* [[Tabalumab]] | * [[Tabalumab]] | ||
* [[Tezepelumab]] | * [[Tezepelumab]] | ||
* [[Ulocuplumab]] | * [[Ulocuplumab]] | ||
* [[Varlilumab]] | * [[Varlilumab]] | ||
* ''Immune activation'': [[Ipilimumab]] | * ''Immune activation'': [[Ipilimumab]] | ||
* [[Durvalumab]] | * [[Durvalumab]] | ||
* [[Nivolumab]] | * [[Nivolumab]] | ||
* [[Tremelimumab]] | |||
* [[Tremelimumab]] | |||
* [[Urelumab]] | * [[Urelumab]] | ||
* ''Other'': [[Bertilimumab]] | * ''Other'': [[Bertilimumab]] | ||
* [[Ontamalimab]] | |||
* [[Zanolimumab]] | * [[Zanolimumab]] | ||
* ''Combination'': [[Nivolumab/relatlimab]] | |||
| group2 = Mouse | | group2 = Mouse | ||
| Line 89: | Line 92: | ||
| group4 = [[Humanized antibody|Humanized]] | | group4 = [[Humanized antibody|Humanized]] | ||
| list4 = | | list4 = | ||
* ''Immunosuppressive:'' | * ''Immunosuppressive:'' [[Apolizumab]]<sup>§</sup> | ||
* [[Aselizumab]] | |||
* [[Atezolizumab]] | |||
* [[Benralizumab]] | * [[Benralizumab]] | ||
* [[Camrelizumab]]<sup>†</sup> | * [[Camrelizumab]]<sup>†</sup> | ||
* [[Cedelizumab]] | * [[Cedelizumab]] | ||
* [[Certolizumab pegol]] | * [[Certolizumab pegol]] | ||
* [[Crizanlizumab]] | * [[Crizanlizumab]] | ||
* [[Daclizumab]] | * [[Daclizumab]] | ||
* [[Eculizumab]] | * [[Eculizumab]] | ||
* [[Efalizumab]]<sup>‡</sup> | * [[Efalizumab]]<sup>‡</sup> | ||
| Line 104: | Line 107: | ||
* [[Etrolizumab]]<sup>†</sup> | * [[Etrolizumab]]<sup>†</sup> | ||
* [[Fontolizumab]] | * [[Fontolizumab]] | ||
* [[Frexalimab]]<sup>†</sup> | |||
* [[Inebilizumab]] | * [[Inebilizumab]] | ||
* [[Itolizumab]] | * [[Itolizumab]] | ||
| Line 113: | Line 117: | ||
* [[Mogamulizumab]] | * [[Mogamulizumab]] | ||
* [[Natalizumab]] | * [[Natalizumab]] | ||
* [[Ocrelizumab]] | * [[Ocrelizumab]] ([[Ocrelizumab/hyaluronidase|+hyaluronidase]]) | ||
* [[Omalizumab]] | * [[Omalizumab]] | ||
* [[Ozoralizumab]] | * [[Ozoralizumab]] | ||
| Line 126: | Line 130: | ||
* [[Ravulizumab]] | * [[Ravulizumab]] | ||
* [[Reslizumab]] | * [[Reslizumab]] | ||
* [[Retifanlimab]] | |||
* [[Rontalizumab]] | * [[Rontalizumab]] | ||
* [[Rovelizumab]] | * [[Rovelizumab]] | ||
| Line 134: | Line 139: | ||
* [[Spartalizumab]]<sup>†</sup> | * [[Spartalizumab]]<sup>†</sup> | ||
* [[Talizumab]] | * [[Talizumab]] | ||
* [[Teclistamab]] | |||
* [[Teplizumab]] | * [[Teplizumab]] | ||
* [[Tislelizumab]] | * [[Tislelizumab]] | ||
| Line 143: | Line 149: | ||
* [[Visilizumab]] | * [[Visilizumab]] | ||
* [[Vobarilizumab]] | * [[Vobarilizumab]] | ||
* [[TGN1412]]<sup>§</sup><br />'' | * [[TGN1412]]<sup>§</sup><br /> | ||
''Immune activation'': [[Dostarlimab]]<br/> | |||
''Other:'' [[Ibalizumab]] | |||
| group5 = Chimeric + humanized<br /> | | group5 = Chimeric + humanized<br /> | ||
| list5 = | | list5 = | ||
* [[Otelixizumab]] | * [[Otelixizumab]] | ||
* [[Sutimlimab]] | * [[Rozanolixizumab]] | ||
* [[Sutimlimab]] | |||
}} | }} | ||
| Line 166: | Line 175: | ||
* [[Secukinumab]] | * [[Secukinumab]] | ||
* [[Sirukumab]] | * [[Sirukumab]] | ||
* [[Tralokinumab]] | * [[Tralokinumab]] | ||
* [[Ustekinumab]] | * [[Ustekinumab]] | ||
| Line 172: | Line 181: | ||
| list2 = | | list2 = | ||
* [[Anrukinzumab]] | * [[Anrukinzumab]] | ||
* [[Bimekizumab]] | * [[Bimekizumab]] | ||
* [[Clazakizumab]] | * [[Clazakizumab]] | ||
* [[Gevokizumab]] | * [[Gevokizumab]] | ||
| Line 181: | Line 190: | ||
* [[Perakizumab]] | * [[Perakizumab]] | ||
* [[Risankizumab]] | * [[Risankizumab]] | ||
* [[Spesolimab]] | |||
* [[Tildrakizumab]] | * [[Tildrakizumab]] | ||
| Line 200: | Line 210: | ||
}} | }} | ||
| belowstyle = | | belowstyle = padding: 0px; | ||
| below = {{PharmNavFootnote}} | | below = {{PharmNavFootnote}} | ||
| Line 207: | Line 217: | ||
[[Category:Monoclonal antibody templates]] | [[Category:Monoclonal antibody templates]] | ||
</noinclude> | </noinclude> | ||
